Home › Funds › EMERALD ADVISERS, LLC › CYTK

EMERALD ADVISERS, LLC position in CYTK

CYTOKINETICS INC · Health Care

EMERALD ADVISERS, LLC reported holding 457,956 shares of CYTK (CYTOKINETICS INC) in its Q2 2026 13F filing — a position valued at US$39.0M, representing 0.92% of its reported portfolio and ranking #41 among its reported holdings. EMERALD ADVISERS, LLC has disclosed CYTK holdings in 3 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)457.96K sh
Reported value held$39.01M
Portfolio Weight0.92%
First reportedQ1 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How EMERALD ADVISERS, LLC's CYTK position evolved

EMERALD ADVISERS, LLC first disclosed a stake in CYTK in Q1 2024 at 91,561 shares (US$6.4M). The position peaked in Q2 2026 at 457,956 shares, worth US$39.0M. Across 3 filings, EMERALD ADVISERS, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 457,956 shares valued at US$39.0M — an increase of 259,145 shares quarter over quarter.. Notable position changes include a 130% increase in Q2 2026 (shares fell 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 91.56K $6.42M New
Q1 2026 198.81K $13.10M New
Q2 2026 457.96K $39.01M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CYTK and 13F data

CYTK (CYTOKINETICS INC) is a Health Care company. 52 other funds we track also report a position in CYTK — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.59B), Avoro Capital Advisors LLC (US$425.9M), RTW INVESTMENTS, LP (US$243.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CYTK

All CYTK fund holders →

FAQ

How long has EMERALD ADVISERS, LLC held CYTK?

EMERALD ADVISERS, LLC has disclosed CYTK holdings in 3 of the last 10 reported quarters, going back to Q1 2024.

What is EMERALD ADVISERS, LLC's current position in CYTK?

As of Q2 2026, EMERALD ADVISERS, LLC holds 457.96K shares of CYTK (CYTOKINETICS INC), valued at $39.01M, representing 0.92% of its reported portfolio and ranking #41.

Has EMERALD ADVISERS, LLC been buying or selling CYTK?

In the latest 13F filing (Q2 2026), EMERALD ADVISERS, LLC increased its position in CYTK. The position peaked in Q2 2026 at 457.96K shares.

Which other funds hold CYTK?

Other major institutional holders of CYTK include T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, among 52 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.